Publikationen in Zusammenarbeit mit Forschern von Royal Marsden Hospital (39)

2024

  1. Management of Adverse Reactions Related to Lenvatinib Plus Pembrolizumab Treatment Among Patients With Renal Cell Carcinoma

    Clinical Genitourinary Cancer

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

    European Urology

  3. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

    European Journal of Cancer

2021

  1. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

    The Lancet Oncology, Vol. 22, Núm. 5, pp. 643-654

  2. COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

    Blood, Vol. 138, Núm. 18, pp. 1768-1773

2020

  1. Cabazitaxel in metastatic prostate cancer

    New England Journal of Medicine

  2. Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3)

    Cancer Medicine, Vol. 9, Núm. 1, pp. 116-124

  3. Outcomes of COVID-19 in patients with CLL: a multicenter international experience

    Blood, Vol. 136, Núm. 10, pp. 1134-1143

2019

  1. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

    The Lancet Oncology, Vol. 20, Núm. 8, pp. 1109-1123

  2. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

    The Lancet Oncology, Vol. 20, Núm. 3, pp. 420-435

2018

  1. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet Oncology, Vol. 19, Núm. 1, pp. 87-100

  2. Reply to 'the St Gallen international expert consensus on the primary therapy of early breast cancer 2017: Te point of view of an international panel of experts in radiation oncology' by Kirova et al.

    Annals of Oncology

2017

  1. De-escalating and escalating treatments for early-stage breast cancer: The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

    Annals of Oncology, Vol. 28, Núm. 8, pp. 1700-1712

  2. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

2016

  1. Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy

    European Journal of Cancer, Vol. 56, pp. 85-92

  2. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

2015

  1. Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyses of individual patient data from randomised trials

    The Lancet, Vol. 386, Núm. 10001, pp. 1353-1361

  2. Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer

    European Journal of Cancer

  3. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy

    Breast Cancer Research, Vol. 17, Núm. 1